Abiopharma

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohns disease at two years

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis

ADC Therapeutics to Present at November Investor Conferences

CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

Incyte annonce de nouveaux résultats issus de l’essai de phase 3b TRuE-AD4 sur Opzelura® (crème à base de ruxolitinib) chez des adultes atteints de dermatite atopique modérée

CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada

Immatics Appoints Amie Krause as Chief People Officer

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025